Therapy Detail

Therapy Name APN401
Therapy Description

APN401 is composed of autologous peripheral blood mononuclear cells in which Cbl-b has been silenced with siRNA, which potentially results in increased anti-tumor immune response upon infusion (J Clin Oncol 34, 2016 (suppl; abstr e14541)).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
APN401 APN401 is composed of autologous peripheral blood mononuclear cells in which Cbl-b has been silenced with siRNA, which potentially results in increased anti-tumor immune response upon infusion (J Clin Oncol 34, 2016 (suppl; abstr e14541)).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable APN401 Phase I Actionable In a Phase I trial, APN401 infusion demonstrated safety in patients with advanced solid tumors, and resulted in stable disease in two patients with pancreatic cancer and one patient with with colorectal cancer (J Clin Oncol 34, 2016 (suppl; abstr e14541)). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT03087591 Phase I APN401 APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery Recruiting